Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients
NCT ID: NCT02035787
Last Updated: 2024-12-18
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
20 participants
INTERVENTIONAL
2014-02-27
2024-04-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants:Women, over the age of 18 years, with biopsy-proven CAH/EC who are not candidates for surgical management, and therefore are planned to start standard of care treatment with the LR-IUD
Procedures (methods): subjects will be given oral metformin therapy for 12 months, or until disease progression occurs (whichever occurs first), in addition to LR-IUD treatment. Serial endometrial biopsies will be performed, as per standard of care, to assess disease status.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
-To compare the rate of CR at 6 months in non-surgical grade 1 EC and CAH patients receiving metformin + LR-IUD to 50%
Secondary Objectives
* to estimate the rate of CR at 6 months separately in grade 1 EC and CAH patients receiving metformin + LR-IUD
* to estimate the rate of CR at 12 months in non-surgical grade 1 EC and CAH patients receiving metformin + LR-IUD
* to document patient adherence to long-term (≥3 months) metformin administration
* To describe safety of metformin + LR-IUD treatment
Exploratory Objectives
* To explore changes in cellular proliferation as measured by the marker, Ki-67, from baseline to 6 months
* To explore association between the level of expression of the metformin transporter proteins and key targets of the metformin/mammalian target of rapamycin (mTOR) signaling pathway and CR status at 6 months
* To perform a comprehensive unbiased profiling of metabolites by analyzing the metabolic "fingerprints" of the biofluids (i.e. serum and urine) and "footprints" of the tumor tissue pre- and post- 6 months of metformin treatment
* To explore association between metabolic factors and metformin concentration levels in tumor tissue/blood/urine and CR at 6 months
This is an open label, single-arm, single-center study of the addition of metformin to standard levonorgestrel-releasing intrauterine device (LR-IUD) treatment of 30 evaluable non-surgical patients with either complex atypical hyperplasia (CAH; n=15) or grade 1 endometrial adenocarcinoma (EC; n=15). Women, over the age of 18 years, with biopsy-proven CAH/EC who are not candidates for surgical management, and therefore are planned to start standard of care treatment with the LR-IUD, will be given oral metformin therapy for 12 months, or until disease progression occurs (whichever occurs first), in addition to LR-IUD treatment. Serial endometrial biopsies will be performed, as per standard of care, to assess disease status. We hypothesize that the addition of metformin to standard LR-IUD treatment of CAH and grade 1 EC will result in a complete response (CR) rate at 6 months that is significantly higher than 50% in a population of non-surgical candidates. In addition, we plan to estimate CR rate at 6 months in CAH and EC separately, and in the group as a whole at 12 months. We will also document the rate of patient adherence to long-term metformin therapy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Metformin
Metformin, 850 mg. twice daily.
Metformin
Metformin added to standard non-surgical treatment with levonorgestrel-Releasing Intrauterine Device.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Metformin
Metformin added to standard non-surgical treatment with levonorgestrel-Releasing Intrauterine Device.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Females age ≥ 18 years
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 - 4
* Non-surgical candidates due to:
* Desire for fertility preserving treatment
* Unacceptable surgical risk as defined by:
* American Society of Anesthesiologists Physical Status (ASA) ≥ 4 and/or Perioperative Cardiac Risk \> 5%(45) and/or Perioperative Respiratory Failure Risk \> 5%(46)
AND
oIndependent medicine or cardiology pre-op consultation concluding 'high' surgical risk.
* Planned treatment with the LR-IUD for CAH or grade 1 EC by primary physician
* Women of childbearing potential (WOCBP) must have negative pregnancy test within 7 days of D1 of treatment
* Understand study design, risks, and benefits and have signed informed consent
Exclusion Criteria
* Currently receiving progestin therapy (local, topical, or systemic)
* Myometrial invasion \>50% or evidence of nodal or metastatic disease on baseline MRI (MRI only to be done for EC patients) or tumor size \> 2cm on MRI or pelvic ultrasound
* Mixed histology including clear cell, serous, undifferentiated or sarcomatous elements
* Prior or current use of metformin within the past 3 months
* History of hypersensitivity to metformin or history of discontinuation secondary to attributed adverse effects
* Chronic (daily use for \> 1 month) use of cimetidine (significant increase in metformin concentration and risk of lactic acidosis)
* Iodinated contrast agents used in prior 48 hours (significant increase in metformin concentration and risk of lactic acidosis)
* Pregnant or lactating
* Recent (\< 4 weeks) active, documented, cervical infection
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Golfers Against Cancer
UNKNOWN
UNC Lineberger Comprehensive Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Victoria Bae-Jump, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
UNC Lineberger Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
TriHealth
Cincinnati, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
University of North Carolina Lineberger Comprehensive Cancer Center Clinical Trials
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
12-0886
Identifier Type: OTHER
Identifier Source: secondary_id
LCCC1326
Identifier Type: -
Identifier Source: org_study_id